Menu Back toSession-5-Endpoint-Evolution-During-Drug-Development-Exit-Interviews-to-Develop-Qualitative-Evidence-for-PRO-Assessments-and-Endpoints
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Advancing the Science of Study Endpoints
Session 5: Endpoint Evolution During Drug Development – Exit Interviews to Develop Qualitative Evidence for PRO Assessments and Endpoints
Ashley F. Slagle, PhD, MS
- Principal, Scientific and Regulatory Consulting
- Aspen Consulting, LLC, United States
Exit interviews of clinical trial participants are becoming increasingly common. There are a number of goals and objectives that might be met using these types of interviews. One important focus of these interviews is to develop qualitative evidence to support PRO assessments and endpoints in trials, however, there are no standard methods to guide this type of work or how the data might be used. This session is intended to introduce participants to the benefits, considerations, and challenges of using exit interviews to generate qualitative data to develop or support PRO assessments and endpoints. Scientific, operational, and regulatory perspectives will be shared. An overview of the types of goals and objectives that can be achieved using exit interviews, as well as appropriate timing across a drug development program will be discussed. Good methods for exit interviews and suggestions for considering and overcoming operational challenges will be provided. Formal presentations will be followed by a panel discussion and audience questions and answers to ensure important issues surrounding this approach to interviews are covered.
Learning Objective : Summarize benefits and opportunities for the use of exit interviews throughout the different phases of drug development
Exit interviews: Benefits, Challenges, and Operational Considerations
Robyn T. Carson, MPH
- Vice President, Patient-Centered Outcomes Research
- Abbvie, United States
Qualitative Evidence Generation Using Exit Interviews in Clinical Trials – Good Practices
Cheryl D. Coon, PhD
- Outcometrix, United States
A Regulatory Perspective on Use of Exit Interviews in Clinical Trials to Generate Qualitative Evidence for PRO Assessments and Endpoints
Elektra Papadopoulos, MD, MPH
- Deputy Director (acting) Division of Clinical Outcome Assessment, OND, CDER
- FDA, United States